StockData
Elite Pharmaceuticals Inc logo

Elite Pharmaceuticals Inc (ELTP) stock

ELTPOTCPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/30
$0.25−0.00 (-1.37%)

Close on Oct 19, 2026Market cap $283.02MP/E 5.0Yield –

Elite Pharmaceuticals profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Elite Pharmaceuticals's profit margin for the twelve months ending Jun 30, 2026 was 40.2%. For fiscal 2026 it was 30.1%, against -5.1% the year before. The highest annual figure on record is 104.1% in fiscal 2015.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2026Mar 31, 202630.1%+35.3
FY2025Mar 31, 2025-5.1%−40.6
FY2024Mar 31, 202435.5%+25.1
FY2023Mar 31, 202310.4%−17.2
FY2022Mar 31, 202227.6%+7.5
FY2021Mar 31, 202120.0%+32.5
FY2020Mar 31, 2020-12.5%+110.2
FY2019Mar 31, 2019-122.6%−73.4
FY2018Mar 31, 2018-49.2%−88.8
FY2017Mar 31, 201739.5%+45.0
FY2016Mar 31, 2016-5.5%−109.6
FY2015Mar 31, 2015104.1%+1000.8
FY2014Mar 31, 2014-896.7%−940.4
FY2013Mar 31, 201343.7%+664.9
FY2012Mar 31, 2012-621.2%−302.8
FY2011Mar 31, 2011-318.4%–

Quarterly profit margin

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange (pts)
Q1 FY2027CQ2 2026Jun 30, 202618.3%+32.9
Q4 FY2026CQ1 2026Mar 31, 202645.3%−7.8
Q3 FY2026CQ4 2025Dec 31, 202558.9%+134.7
Q2 FY2026CQ3 2025Sep 30, 202537.7%+96.2
Q1 FY2026CQ2 2025Jun 30, 2025-14.6%−17.9
Q4 FY2025CQ1 2025Mar 31, 202553.1%+34.6
Q3 FY2025CQ4 2024Dec 31, 2024-75.8%−80.4
Q2 FY2025CQ3 2024Sep 30, 2024-58.5%−163.9
Q1 FY2025CQ2 2024Jun 30, 20243.3%−9.4
Q4 FY2024CQ1 2024Mar 31, 202418.5%+32.8
Q3 FY2024CQ4 2023Dec 31, 20234.5%−27.6
Q2 FY2024CQ3 2023Sep 30, 2023105.5%+87.8
Q1 FY2024CQ2 2023Jun 30, 202312.7%+8.7
Q4 FY2023CQ1 2023Mar 31, 2023-14.2%−45.9
Q3 FY2023CQ4 2022Dec 31, 202232.1%+6.7
Q2 FY2023CQ3 2022Sep 30, 202217.6%−3.3
Q1 FY2023CQ2 2022Jun 30, 20224.0%−29.9
Q4 FY2022CQ1 2022Mar 31, 202231.7%+42.6
Q3 FY2022CQ4 2021Dec 31, 202125.4%−7.8
Q2 FY2022CQ3 2021Sep 30, 202121.0%−12.5
Q1 FY2022CQ2 2021Jun 30, 202133.9%+19.6
Q4 FY2021CQ1 2021Mar 31, 2021-11.0%−29.9
Q3 FY2021CQ4 2020Dec 31, 202033.3%+70.1
Q2 FY2021CQ3 2020Sep 30, 202033.5%+68.0
Q1 FY2021CQ2 2020Jun 30, 202014.3%+6.0
Q4 FY2020CQ1 2020Mar 31, 202018.9%+217.2
Q3 FY2020CQ4 2019Dec 31, 2019-36.8%+50.2
Q2 FY2020CQ3 2019Sep 30, 2019-34.4%+155.1
Q1 FY2020CQ2 2019Jun 30, 20198.3%+86.2
Q4 FY2019CQ1 2019Mar 31, 2019-198.2%−21.1
Q3 FY2019CQ4 2018Dec 31, 2018-87.0%−67.7
Q2 FY2019CQ3 2018Sep 30, 2018-189.5%−301.3
Q1 FY2019CQ2 2018Jun 30, 2018-77.9%+49.5
Q4 FY2018CQ1 2018Mar 31, 2018-177.1%+58.9
Q3 FY2018CQ4 2017Dec 31, 2017-19.3%−90.8
Q2 FY2018CQ3 2017Sep 30, 2017111.8%−46.0
Q1 FY2018CQ2 2017Jun 30, 2017-127.4%–
Q4 FY2017CQ1 2017Mar 31, 2017-236.0%–
Q3 FY2017CQ4 2016Dec 31, 201671.5%–
Q2 FY2017CQ3 2016Sep 30, 2016157.8%–

More Elite Pharmaceuticals figures

See a number that looks wrong?